Contract Manufacturing

Accelerating the path to first-in-human clinical trials

23-Apr-2019 By Melissa Fassbender

On the path to first-in-human clinical trials one of the main challenges is “velocity, ensuring rapid delivery of delivered drug product into the clinical program,” says CDMO.

HPAPI market to reach $26bn in 2023: CDMOs need to ‘gear up’ to support future demands

23-Apr-2019 By Melissa Fassbender

Oncology and immunotherapies are the top two indications for global clinical research – and are driving a significant growth in the market demand for HPAPIs, says Patheon executive.

WuXi and I-Mab extend partnership to accelerate biologic development

18-Apr-2019 By Maggie Lynch

I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.

Vetter’s Chicago-based manufacturing facility expansion to meet the region’s CDMO needs

18-Apr-2019 By Maggie Lynch

Completion of early-stage development site expansion at the Illinois Science and Technology Park supplies Chicago-based drug companies with refrigeration services for complex APIs.

Clinical research is a 'dance you learn as you go': ACRP 2019

18-Apr-2019 By Maggie Lynch

Live updates from the leaders and speakers of the clinical research industry this past week in Nashville, TN, as they discuss the past, present, and future of clinical research as it continues to grow, evolve, and become patient-centric.

MHRA approves Sharp’s clinical services center in Wales

16-Apr-2019 By Maggie Lynch

Sharp’s clinical services center is approved by the MHRA and now ready to offer services for serialization and trial management while reducing carbon footprint with the addition of solar panel systems.

Manufacturing and the microbiome: Lonza, Chr. Hansen set out to pioneer the live biotherapeutic products industry

11-Apr-2019 By Melissa Fassbender

Bringing together the food industry’s know-how and pharma’s manufacturing expertise, the new joint venture from Lonza and Chr. Hansen is positioned to pioneer the live biotherapeutic products space – addressing medical needs not met with ‘conventional’...

CDMO collaborates with synthetic DNA provider for biologic drug development

08-Apr-2019 By Maggie Lynch

Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.

UK CDMO Sterling Pharma Solutions acquires US facility

04-Apr-2019 By Melissa Fassbender

With 70% of its customers in North America and demand increasing, the UK-based CDMO Sterling Pharma Solutions has acquired CiVentiChem’s US facility in Cary, North Carolina.

People on the Move: Outsourcing-Pharma roundup March ‘19

29-Mar-2019 By Melissa Fassbender

The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.

Brammer acquisition bolsters Thermo Fisher place in the market

29-Mar-2019 By Maggie Lynch

Thermo Fisher’s $1.7bn acquisition bolsters its ‘already strong position’ in the cell and gene therapy market, with increased CDMO capabilities.

WuXi STA tapped as preferred partner for Beta Pharma

21-Mar-2019 By Melissa Fassbender

WuXi STA becomes the preferred CDMO partner for Beta Pharma as the company launches a Phase II clinical trial in China and begins preclinical research for an additional target.

Lonza teams with hospital to produce CAR-T cells at point-of-care

18-Mar-2019 By Maggie Lynch

Lonza and Israel-based Sheba Medical collaborate to use the CDMO’s manufacturing platform for point-of-care genetically engineered human CAR-T cell production.

At the source: Harmonizing clinical partnership strategy and procurement

18-Mar-2019 By Maggie Lynch

Alternatives to the transactional RFP-bid defense structure “invite greater creativity and innovative options” into sourcing discussions, says Syneos executive.